Rebecca Kate Harston, Ph.D., is an accomplished executive leader, biotechnology strategist, and trusted advisor with 17 years of professional experience driving enterprise growth, commercial innovation, and strategic partnerships across the biotechnology, biopharmaceutical, life sciences, and public health sectors. With a career distinguished by scientific expertise, executive leadership, and a deep understanding of government and commercial markets, Rebecca has established herself as a respected voice in translating complex scientific advancements into sustainable business opportunities. Her professional journey reflects a commitment to advancing healthcare innovation, strengthening organizational capabilities, and connecting scientific discovery with meaningful societal impact.

Rebecca currently serves as Founder and Principal of Blue Ridge BioStrategies, LLC, a strategic advisory firm supporting biotechnology, pharmaceutical, life sciences, and mission-driven organizations. In this capacity, she advises executive leadership teams on commercialization, portfolio development, business growth, strategic partnerships, and market positioning. Her work emphasizes navigating complex government markets, identifying federal and nondilutive funding opportunities, and helping organizations align innovative technologies with evolving public health priorities. Through her advisory practice, Rebecca brings together scientific understanding, commercial judgment, and cross-sector relationships to help organizations pursue responsible growth and long-term sustainability.

Before establishing Blue Ridge BioStrategies, Rebecca held senior executive leadership positions with Thermo Fisher Scientific and PPD, where she helped shape enterprise commercial strategy across government and public health markets. As Executive Director of Government and Public Health Commercial Strategy, she provided strategic direction for initiatives involving federal healthcare agencies, research institutions, nonprofit organizations, and global public health stakeholders. Her responsibilities included coordinating multidisciplinary capabilities spanning clinical research, laboratory services, manufacturing, digital solutions, and professional services. Working within a global organization and collaborating across large-scale enterprise operations, she developed a sophisticated understanding of how complex organizations align resources, manage competing priorities, and pursue sustainable growth.

Throughout her tenure at Thermo Fisher Scientific and PPD, Rebecca contributed to significant commercial achievements and organizational advancements. In 2025, her leadership efforts supported 27 contract awards totaling approximately $110 million, representing a competitive success rate of 69.23% despite challenging federal funding conditions. She also helped develop a government-focused professional services operating model designed to expand federal staffing and specialized service capabilities. Her ability to integrate diverse business functions, strengthen executive relationships, and identify emerging market opportunities helped position the organization for continued growth across government, nonprofit, biodefense, and global health markets.

Earlier in her career, Rebecca spent more than nine years with Advanced BioScience Laboratories, Inc., progressing through increasingly responsible positions in marketing, communications, proposal management, and business development. Ultimately serving as Director of Business Development, she directed federal market expansion, capture strategy, competitive positioning, and strategic proposal execution. Her contributions included expanding the government business pipeline by more than 370% and supporting more than $300 million in federal contract awards. She also led enterprise rebranding, digital marketing initiatives, pricing strategy, and market-entry efforts that supported sustained double-digit commercial growth. This progression from operational and functional leadership into enterprise-level strategy established a strong foundation for her subsequent executive responsibilities.

A defining characteristic of Rebecca’s leadership is her ability to operate effectively at the intersection of science, business, and government policy. Her experience spans federal healthcare, biotechnology commercialization, biodefense, medical countermeasures, biosecurity, and public health preparedness. She has worked across complex markets involving organizations such as the National Institutes of Health, Biomedical Advanced Research and Development Authority, Department of Defense, Defense Health Agency, and Advanced Research Projects Agency for Health. Through these engagements, she has developed expertise in understanding funding mechanisms, evaluating market opportunities, navigating institutional priorities, and positioning organizations to build meaningful partnerships with government and industry stakeholders.

Rebecca’s professional accomplishments also reflect an ability to influence enterprise strategy beyond traditional business development. She has contributed to strategic initiatives involving acquisition and partnership evaluations, long-range commercial forecasting, integrated service models, and organizational transformation. Her work has included supporting the development and implementation of a major adaptive platform clinical trial during the COVID-19 response, as well as coordinating cross-enterprise opportunities representing hundreds of millions of dollars in potential business. Across her career, her efforts have contributed to more than $1 billion in federal contract awards, demonstrating the scale of her experience in competitive markets and complex institutional environments.

Rebecca’s executive achievements are grounded in a rigorous scientific education and an early career dedicated to biomedical research. She earned her Doctor of Philosophy in Biomedical Sciences from the Medical University of South Carolina and graduated Cum Laude with a Bachelor of Science in Biological Sciences from Clemson University. During her research career, she investigated cardiovascular biology, molecular signaling pathways, cardiac hypertrophy, and mechanisms involved in cellular survival. Her scientific contributions included developing experimental models, preparing research grants, authoring scientific manuscripts, and submitting a provisional patent related to a potential heart failure therapy. She has also contributed to scientific publications and presentations involving cardiovascular biology, immunology, molecular signaling, and translational biomedical sciences.

Her combination of scientific and commercial expertise provides a distinctive perspective on the challenges facing biotechnology and biopharmaceutical organizations. Rebecca understands that scientific innovation alone does not guarantee commercial success; organizations must also establish clear market strategies, secure appropriate funding, build effective partnerships, and develop scalable operating models. Her background enables her to evaluate opportunities through multiple lenses, considering scientific feasibility, institutional priorities, competitive dynamics, financial sustainability, and long-term organizational value. This multidisciplinary approach is particularly relevant to established biotechnology companies seeking expansion, organizations entering government markets, and nonprofits working to translate scientific progress into measurable public health outcomes.

Rebecca’s leadership has received notable professional recognition, including four consecutive President’s Club honors from 2020 through 2023 and the distinction of Biopharma Representative of the Year in 2022. Her career has also included recognition for executive influence, commercial leadership, and contributions to organizational growth. Beyond individual accomplishments, she has invested in developing emerging leaders, mentoring business development professionals, and strengthening organizational capabilities. Her professional affiliations have included the Maryland Tech Council’s Government Relations Committee, the Association of Proposal Management Professionals, the National Defense Industrial Association, and the American Marketing Association, reflecting her engagement across business, government, and professional communities.

As she expands her focus toward board and strategic advisory opportunities, Rebecca is particularly interested in supporting biotechnology, biopharmaceutical, medical technology, and mission-driven nonprofit organizations. She is especially drawn to established biotechnology enterprises and organizations seeking to strengthen commercialization, navigate complex funding environments, or accelerate strategic growth. Her experience working with global organizations, Fortune 500-scale enterprises, government agencies, and nonprofit stakeholders provides a broad perspective on governance considerations, enterprise risk, resource allocation, and organizational performance. Although she is pursuing her first formal board appointment, she brings extensive experience advising senior executives and influencing strategic decisions across complex organizations.

Rebecca approaches leadership with an appreciation for collaboration, accountability, and the importance of connecting organizational objectives with a larger purpose. Her professional interests extend beyond financial performance to include public health advancement, scientific progress, and the development of sustainable solutions that benefit communities. Outside her professional responsibilities, she enjoys coaching and hiking, interests that complement her commitment to personal development, mentorship, perseverance, and maintaining a balanced perspective. These pursuits reflect the same curiosity, resilience, and dedication to growth that have shaped her professional journey.

Looking ahead, Rebecca seeks opportunities to contribute her experience to organizations positioned to make meaningful advances in biotechnology, healthcare, and public health. She recognizes that effective board leadership requires thoughtful questioning, strategic foresight, collaborative decision-making, and a willingness to evaluate both opportunities and risks. Her combination of doctoral-level scientific training, executive commercial leadership, government funding expertise, and experience navigating global enterprise environments positions her to offer valuable insights to leadership teams and boards. Guided by a commitment to responsible innovation and purpose-driven growth, Rebecca aspires to help organizations strengthen their strategic direction, expand their influence, and create lasting value for stakeholders and the communities they serve.

Character:
Rebecca demonstrates integrity, resilience, and a commitment to advancing organizations whose work contributes to scientific progress and public well-being. Her leadership reflects accountability, a collaborative mindset, and a dedication to mentoring others while pursuing meaningful and sustainable organizational outcomes.

Knowledge:
Rebecca brings a combination of doctoral-level biomedical expertise and 17 years of experience spanning biotechnology, biopharmaceutical commercialization, government contracting, and public health strategy. Her understanding of scientific innovation, federal funding pathways, enterprise operations, and complex market dynamics enables her to provide informed perspectives on organizational challenges and growth opportunities.

Strategic:
Rebecca excels at identifying market opportunities, developing competitive growth strategies, and aligning multidisciplinary resources to achieve enterprise objectives. Her experience expanding business pipelines, supporting major federal contract awards, and guiding cross-functional initiatives demonstrates her ability to translate complex challenges into actionable strategies that support long-term success.

Communication:
Rebecca is an effective executive communicator who connects scientific, commercial, and government stakeholders through clear messaging, thoughtful engagement, and collaborative leadership. Her experience in scientific publishing, professional presentations, strategic partnerships, and executive advisory work demonstrates her ability to communicate complex ideas persuasively while building trust across diverse audiences.